Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

GRAIL, Inc.(GRAL US)

$132.55+5.494.32%Ext:$133.89+1.341.01%(Market Closed · 23:55:40 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
GRAL US​

GRAIL, Inc. — Company Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UQ
CEO
Joshua J. Ofman
Headquarters
Menlo Park, CA, US
IPO Date
Jun 12, 2024
Employees
910
Website
www.grail.com

Key Metrics

Price
$147.49
Market Cap
$6.33B
Revenue (TTM)
$40.78M
Net Income (TTM)
$-93187000.00
EPS (TTM)
-2.29
P/E (TTM)
-16.01
P/B (TTM)
2.53
Dividend Yield
0.00%
ROE (TTM)
-3.73%
ROA (TTM)
-3.32%
Operating Margin
-3.33%
Beta
2.59

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Website
www.grail.com
Location
Menlo Park, CA, US
Phone833-694-2553
Employees910
CEOJoshua J. Ofman
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateJun 12, 2024

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(257)

Expand
  • 4Statement of changes in beneficial ownership16 Oct
  • 4Statement of changes in beneficial ownership16 Oct
  • 4Statement of changes in beneficial ownership16 Oct
  • 4Statement of changes in beneficial ownership16 Oct
  • 144Ofman Joshua J.15 Oct
  • 4Statement of changes in beneficial ownership7 Oct
  • 4Statement of changes in beneficial ownership7 Oct
  • 144Partridge Andrew John5 Oct
  • 144Freidin Aaron5 Oct
  • 4Statement of changes in beneficial ownership23 Sep
  • 4Statement of changes in beneficial ownership23 Sep
  • 144Ofman Joshua J.21 Sep
  • 4Statement of changes in beneficial ownership31 Aug
  • 4Statement of changes in beneficial ownership31 Aug
  • 144Ofman Joshua J.27 Aug
  • 144Freidin Aaron27 Aug
  • SC 13G/AGRAIL, Inc.13 Aug
  • SC 13GGRAIL, Inc.7 Aug
  • SC 13G/AGRAIL, Inc.6 Aug
  • 10-QQ2ended 30 Jun 20266 Aug

News

  • GRAIL to Announce Third Quarter 2026 Financial Results21 Oct
  • GRAIL (NASDAQ:GRAL) Stock: Insider Joshua Ofman Sells 20,000 Shares18 Oct
  • GRAIL (NASDAQ:GRAL) Stock Price Down 5.6% on Insider Selling18 Oct
  • 11 Stocks Most Likely to See a Short Squeeze Rally12 Oct
  • First-Class Amenity Kits Have Become Holy Grail Collectibles12 Oct
  • Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.11 Oct
  • Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL)11 Oct
  • 2 Growth Stocks to Buy in October8 Oct
  • Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase7 Oct
  • GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 20265 Oct
  • Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?4 Oct
  • GRAIL (NASDAQ:GRAL) Shares Climb 5.5% – Time to Buy?2 Oct
  • GRAIL (NASDAQ:GRAL) Hits New 12-Month High – Should You Buy?1 Oct
  • 3 Reasons to Buy Grail (GRAL) Hand Over Fist in October30 Sep
  • Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.30 Sep
  • Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock26 Sep
  • Here's Why Grail Stock Surged 55% This Week25 Sep
  • GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 61,452 Shares24 Sep
  • Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn't?24 Sep
  • Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval23 Sep

Mentions in Filings

  • Gravitics’ Orbital Carrier is expected to be a game-changing platform that enables the U.S. Space Force to stage and execute counterspace operations-the holy <strong>grail</strong> in achieving space superiority as referenced in U.S. Space Force’s *Space Warfighting: A Framework for Planners (March 2025).* Gravitics is developing the Orbital Carrier to enable rapid response in earth orbit and cislunar space. Orbital Carriers pre-position, host, protect, deliver, …
    NON INVASIVE MONITORING SYSTEMS INC /FL/GRAIL, Inc.·S-1/A - Registration statement (general form, amendment)·Q4 26·19 Oct
  • Gravitics’ Orbital Carrier is expected to be a game-changing platform that enables the U.S. Space Force to stage and execute counterspace operations—the holy <strong>grail</strong> in achieving space superiority as referenced in U.S. Space Force’s *Space Warfighting: A Framework for Planners (March 2025).* Gravitics is developing the Orbital Carrier to enable ***rapid response*** in earth orbit and cislunar space. Orbital Carriers pre-position, host, protect, del …
    NON INVASIVE MONITORING SYSTEMS INC /FL/GRAIL, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·19 Oct
  • … sciences, Inc. since February 2010. He has served as chair of those boards since July 2019, December 2011, and May 2011, respectively. Dr. Rastetter previously served as the Interim Chief Executive Officer and Chairman of <strong>Grail</strong>, Inc., and as a member of the board of directors of Regulus Therapeutics, Inc. from April 2013 until its acquisition by Novartis AG in June 2025. Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 …
    Iambic Therapeutics, Inc.GRAIL, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·15 Oct
  • … 448M Capricor Therapeutics CAPR 4 +138% $383M Arcturus Therapeutics ARCT 5 +128% $6.2B Kodiak Sciences KOD 6 +115% $667M Chaince Digital CD 7 +111% $10.0B Twist Bioscience TWST 8 +105% $2.0B Schrödinger SDGR 9 +104% $6.0B <strong>GRAIL</strong> GRAL 10 Price return, Jul 31 to Sept 30, 2026 (August and September), about 2,000 companies Deep daily liquidity in both ASST and SATA Average daily dollar volume, last 30 trading days Average daily dollar volume = daily …
    Strive, Inc.GRAIL, Inc.·FWP - Free writing prospectus·Q4 26·13 Oct
  • Gravitics’ Orbital Carrier is expected to be a game-changing platform that enables the U.S. Space Force to stage and execute counterspace operations-the holy <strong>grail</strong> in achieving space superiority as referenced in U.S. Space Force’s *Space Warfighting: A Framework for Planners (March 2025).* Gravitics is developing the Orbital Carrier to enable rapid response in earth orbit and cislunar space. Orbital Carriers pre-position, host, protect, deliver, …
    NON INVASIVE MONITORING SYSTEMS INC /FL/GRAIL, Inc.·S-1/A - Registration statement (general form, amendment)·Q4 26·9 Oct
  • Gravitics’ Orbital Carrier is expected to be a game-changing platform that enables the U.S. Space Force to stage and execute counterspace operations—the holy <strong>grail</strong> in achieving space superiority as referenced in U.S. Space Force’s *Space Warfighting: A Framework for Planners (March 2025).* Gravitics is developing the Orbital Carrier to enable ***rapid response*** in earth orbit and cislunar space. Orbital Carriers pre-position, host, protect, del …
    NON INVASIVE MONITORING SYSTEMS INC /FL/GRAIL, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·9 Oct

Key Stats

Trading

Px/Chg 1D$147.49 / +2.95%
Avg Volume1.12M
Beta2.59
Mkt Cap6.33B
FD Mkt Cap3.37B

Float

Shrs Out/Float42.92M / 39.29M
Short Float0.20%
Days to Cover11.10
Stock Repurchased$0.00

Current Valuation

EV6.31B
EV/EBITDA-18.69
EV/Sales40.43
P/B2.53
P/S40.54
FCF Yield-1.38%
ROE-3.73%
ROA-3.32%
Current Ratio11.74

Estimates

P/E-16.01
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-31.46-0.68-25.77-67.92
Price / Sales74.9010.8958.62155.19
Price / Book Value1.360.550.992.53
Price / Free Cash Flow-38.43-2.35-40.58-72.34
ENTERPRISE VALUE METRICS
Enterprise Value3,312.41,222.22,403.86,311.2
Enterprise Value / Sales73.209.7355.14154.74
Enterprise Value / EBITDA-34.70-2.00-30.97-71.13
Enterprise Value / EBIT-23.90-1.59-20.63-49.49

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue78.1%14.655.693.1125.6147.2
Gross Income-11.1%-100.0-116.4-95.6-78.0-62.6
EBITDA-25.2%-1,206.8-587.7-638.2-610.2-378.2
EBIT-19.4%-1,265.3-742.5-796.9-768.2-534.5
Net Income-24.4%-1,247.8-5,399.1-1,465.7-2,027.0-408.4
EPS (Diluted)-27.5%-40.18-173.87-47.20-63.54-11.11
BALANCE SHEET
Cash & ST Inv42.2%221.2241.697.3763.5904.4
Total Assets-26%9,737.95,602.14,556.92,983.32,922.0
Total Liabilities2.9%307.4955.9910.7479.9344.2
Total Shareholder Equity-27.7%9,430.54,646.23,646.22,503.42,577.9
CASH FLOW
Net Operating Cash Flow-18.8%-688.1-561.3-595.8-577.2-299.0
Cap Ex-66.2%-69.9-22.9-12.9-5.2-0.9
Free Cash Flow-20.8%-758.1-584.2-608.7-582.4-299.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)132.55
Basic Shares42.92
Market Cap5,688.6
Diluted Shares40.64
Fully Diluted Shares Outstanding40.64
Fully Diluted Market Cap5,386.9
+Consolidated Debt51.0
−In-the-Money Convertible Debt—
+Capital Leases9.9
+Operating Leases—
−Cash & Equivalents-69.3
−Short-term Investments-753.8
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value5,670.3

Segment data

Revenue

by Geography

  • United States94%
  • Non-us6%

Related companies

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

RadNet, Inc.

RDNT US

Sotera Health Co

SHC US

Vontier Corp

VNT US

DiaSorin S.p.A.

DSRLF US